Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activities No serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos’ Proprietary […]
AI-based Small Molecule Therapeutics Pioneer Athos Therapeutics Selects Vultr for Secure AI Training in the Cloud
Athos accelerates the development of precision therapeutics for patients with immune-mediated diseases and cancer by scaling its autonomous AI analytical platform WEST PALM BEACH, Fla.–(BUSINESS WIRE)–Vultr, the world’s largest, privately-held cloud computing platform, today announced that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to run its AI model training, tuning, and […]
Athos Therapeutics Announces the Autonomization of their Artificial Intelligence and Machine Learning Platforms
The Athos Computational Platforms are now Disease Agnostic with an AI/ML framework powered by Autonomous Transcriptomics and Proteomics able to Integrate and Learn from Diverse Multi-Omic Data Domains LOS ANGELES, March 5, 2024 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of Artificial Intelligence (AI) and Machine Learning (ML)-based precision […]
Laurence Stein, Former Partner and Managing Director of Goldman Sachs, Appointed to the Board of Directors of Athos Therapeutics
LOS ANGELES, February 13, 2024 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that Laurence Stein, has been named to the Company’s Board of Directors and will serve as Head of its Business Strategy […]
All Three Athos Co-Founders Named to Stanford’s List of the World’s Top 2% of Scientists
LOS ANGELES, CA / ACCESSWIRE / October 12, 2023 / Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that each one of the three co-founders of Athos has been named to Stanford University’s prestigious “Top 2%” […]
Athos Student Internship Program
The internship program was designed to expose students to Athos’s unique, innovative, and diverse interdisciplinary approach to science and drug development, and to create a bridge for students between academia and the professional world. We provide invaluable and practical experiences such as how to pipette and use scientific equipment, how to create different concentrations of […]
Tony Zingale, Noted Chief Executive Officer and Entrepreneur, Appointed as an Observer to the Board of Directors of Athos Therapeutics
LOS ANGELES, May 17, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that Tony Zingale, a veteran software executive, was appointed as an observer to the Board of Directors of Athos Therapeutics. “Athos […]
Athos Therapeutics Announces Dosing of the First Patient in the First-In-Human Phase 1 Clinical Trial of ATH-063
ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn’s disease – 27 April 2023, 11:30 am ET LOS ANGELES, April 27, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics […]
Athos Therapeutics Announces Research Collaboration with the University of Ioannina to Advance the Field of Inflammatory Bowel Disease
Athos to perform molecular and computational analyses of patient biomaterials from de-identified Inflammatory Bowel Disease patient samples from the Faculty of Medicine, School of Health Sciences and the Division of Gastroenterology at the University Hospital of Ioannina based in Ioannina, Greece. 19 April, 11:00 am ET LOS ANGELES, April 19, 2023 — Athos Therapeutics, Inc. (“Athos”), […]
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn’s disease – 29 March 2023, 11:30 am ET LOS ANGELES, March 29, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule […]